Skip to main content

Wangbi granule as a combination therapy to achieve clinical deep remission in rheumatoid arthritis: protocol for a multicenter, triple-blind, randomised, placebo-controlled trial



Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that may lead to bone erosion and disability. Although there are many biological therapies in RA treatment nowadays, such as etanercept and tofacitinib, there are still a considerable number of patients who cannot achieve clinical deep remission, which makes patients feel pain and stiffness of joints. As a traditional Chinese medicine preparation, Wangbi granule showed a synergistic role with methotrexate in the treatment of RA patients with “kidney deficiency and dampness” or “stasis blocking channels”. Therefore, it is a promising therapeutic strategy for the clinical deep remission of RA. In this study, Wangbi granule will be used as the test drug. The investigators conduct this study to evaluate the efficacy and safety of Wangbi granule in the treatment of patients who have not achieved deep remission despite the use of methotrexate and tofacitinib.

Methods and analysis

Two parallel randomized, triple-blind, placebo-controlled trials will be conducted. In six study centers, 340 eligible RA patients will be recruited and randomly allocated to either the intervention group or the control group (in a 1:1 ratio). They will receive Wangbi granule or Wangbi placebo 12.0 g each time, three times a day for 12 weeks. The primary outcome is the disease activity score derivative for 28 joints (DAS28). Secondary outcomes are patient-reported outcomes, American College of Rheumatology 50% response criteria (ACR50), fatigue scale-14 (FS-14), visual analogue scale for pain (VAS), health assessment questionnaire disability index (HAQ-DI) and biomarkers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Expected outcomes

The success of this study will provide strong evidence to confirm the efficacy and safety of Wangbi granule in the treatment of RA.

Trial registration The trial has been registered in the ClinicalTrials Registry (NCT05540938, Date: 09/15/2022,


Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease and is currently one of the major disabling diseases worldwide, with a prevalence of about 1% [1, 2]. RA is mainly manifested as chronic synovial inflammation, which undergoes synovial proliferation, infiltration of immune and inflammatory cells, and eventually progresses to destruction of cartilage and bone, resulting in limited joint movement and physical disability [3]. Disease activity and bone erosion in RA have been the most important clinical concerns. Reducing disease activity, controlling synovial inflammation, and delaying bone destruction are the crucial issues that need to be addressed.

The standard of care for RA has gone through phases of hormones, non-steroidal antiinflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs) and target-mediated drug for small molecules [4]. The prognosis of RA has been improved substantially due to the appearance of bDMARDs and target-mediated drug for small molecules. However, once RA is controlled, dose reduction or withdrawal of these drugs must be taken into consideration because of infection risk, dose-dependent adverse events, or treatment cost. More importantly, during the treatment process, even after intensive Western medication, there are a considerable number of patients who cannot achieve clinical deep remission, which makes patients still feel pain and stiffness of joints [5], and gradually lead to a series of complications such as chronic fatigue and diffuse pain [6, 7]. In the case of the methotrexate combined with tofacitinib regimen, for example, a study demonstrated that even with the application of this more therapeutically potent intervention, only 46% of patients could achieve an American College of Rheumatology 50% response criteria (ACR50) after 6 months of treatment, and 7% of patients experienced adverse events [8]. Therefore, finding new treatment options to achieve deep remission in RA patients, and relieve chronic fatigue and diffuse pain based on current treatment is an urgent issue for clinicians to address.

Chinese medicine is effective in the treatment of RA, with relatively mild side effects and suitable for long-term use [9]. The Wangbi granule, a well-known Chinese patent medicine, was developed by Liaoning Good Nurse Pharmaceutical (Group) Co., Ltd. (Benxi City, Liaoning Province, China) and approved by the China Food and Drug Administration (No: Liao20150121) for the treatment of RA [10]. The latest research has shown that Wangbi granule has impressive anti-inflammatory and immunomodulatory effects and can reduce pathological hyperplasia and bone destruction in damaged joints [11, 12]. As a traditional Chinese medicine preparation, Wangbi granule showed a synergistic role with methotrexate in the clinical treatment of early RA, contributing to the remission of RA [13]. However, stronger evidence is needed to confirm its further therapeutic effects in RA that has been treated but not yet reached a complete remission. This will help clinicians to better manage the course of RA patients.

In conclusion, the investigators will conduct this randomized controlled trial to evaluate the efficacy and safety of Wangbi granule in RA patients who did not achieve deep remission despite treatment with tofacitinib and methotrexate.


Study design

The clinical study of Wangbi granule for RA is a multicenter, randomised, triple-blind, placebo-controlled superiority trial. The study flow is designed strictly according to the CONSORT Statement and SPIRIT Statement [14, 15] (Fig. 1). The study will restrict the enrollment of participants, use strict randomization and blinding, and apply some statistical methods to prevent possible bias in these ways.

Fig. 1
figure 1

The flow diagram of the trial. T0, 0–1 day treatment (baseline); T1, 4 week treatment; T2, 8 week treatment; T3, 12 week treatment; T4, 1 month after end of treatment; DAS28 disease activity score derivative for 28 joints, ACR50 American College of Rheumatology 50% response criteria, VAS visual analogue scale for pain, FS-14 fatigue scale-14, HAQ-DI health assessment questionnaire disability index, ALT alanine aminotransferase, AST aspartate aminotransferase, Scr serum creatinine, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factors, ACPA anti-citrullinated protein antibodies

Eligibility criteria

Patients aged 18–75 years who meet the 1987 or 2010 international diagnostic criteria for RA are eligible for the study [16, 17]. Patients need to meet the diagnostic criteria (2018 edition) for “kidney deficiency and dampness” and “stasis blocking channels” in Chinese medicine [18]. The disease activity score derivative for 28 joints (DAS28) [19] score should be 2.6 to 3.2. The use of methotrexate (7.5–15 mg, quaque week, dose changes with disease) in combination with tofacitinib (5 mg, bis in die) for more than 12 weeks prior to recruitment is required. Before recruitment, clear notification and signing of informed consent are required.

Exclusion criteria include: taking immunosuppressants other than methotrexate and tofacitinib in the 3 months prior to recruitment; combination of other severe multi-system damaging diseases; presence of cognitive impairment, psychosomatic disorders, peripheral neurological disorders; those who are pregnant, breastfeeding, or have a planned pregnancy; overweight, allergic to the study drug, or enrolled in another clinical trial; other conditions in which the investigator believes the patient should not participate in the trial. The complete list of inclusion and exclusion criteria is provided in Table 1.

Table 1 Inclusion and exclusion criteria of the trial

Participants may decide to withdraw from the trial at any time for any reason of their own choosing. The investigators may also ask the participant to withdraw from the trial for rational reasons. All participants who have completed the informed consent form and are screened and qualified to enter the randomized trial, regardless of when and why they withdrew, will be treated as dislodged cases as long as they do not complete the observation period specified in the protocol.

Study setting

This trial is led by the Traditional Chinese Medicine Department of Rheumatology at China-Japan Friendship Hospital and will be conducted at 6 hospitals in China (China-Japan Friendship Hospital, Peking Union Medical College Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, The 980th Hospital of PLA Joint Logistics Support Force, The Second Affiliated Hospital of Zhejiang Chinese Medical University, and The First Hospital Affiliated to Army Medical University).


A total of 340 patients will be recruited from the 6 centers participating in this study. An investigator, assisted by a trained study coordinator at each participating center, will identify potential eligible patients based on the eligibility criteria. They will work with the attending physician to determine whether the patient is eligible for the trial. Patients who travel to outpatient or inpatient settings for RA are evaluated for eligibility by an investigator who collects relevant information face-to-face with the patient’s verbal consent at the time of treatment. If RA patients are recruited from posters, the internet, etc., eligibility will be assessed over the phone. After the patient is deemed to meet the criteria for participation, the investigator will inform the study protocol in detail, at which point potential participants can ask their questions and requests, and after formally signing written informed consent, they are enrolled in the trial as participants.


After being recruited, patients will be randomly allocated to either the intervention group or the control group (in a 1:1 ratio).

Based on the treatment of methotrexate (7.5–15 mg, quaque week, dose changes with disease) (Shanghai Sine Pharmaceutical, Shanghai, China) and tofacitinib (5 mg, bis in die) (Qilu Pharmaceutical, Shandong, China), patients in the intervention group will be given Wangbi granule (12 g, ter in die) (Good Nurse Pharmaceutical, Liaoning, China) and patients in the control group will be given Wangbi placebo (12 g, ter in die) (Good Nurse Pharmaceutical, Liaoning, China). To reduce the adverse effects of methotrexate, folic acid (10 mg, quaque week) (Lisheng Pharmaceutical, Tianjin, China) will be used in combination with all treatments.

All the botanical or zoological drugs that make up the Wangbi granule are explained in Table 2. All trial drugs will be manufactured and supplied by Liaoning Good Nurse Pharmaceutical (Group) Co., Ltd. (Benxi City, Liaoning Province, China) and tested by its quality management department to meet the Pharmacopoeia of China (2020 edition) grade standards. Voucher samples of all drugs will be stored at China-Japan Friendship Hospital (Beijing, China). The drug preparation and packaging will be operated by the pharmacy of Good Nurse Pharmaceutical in a fully enclosed production line. All ingredients will be mixed in the original dosage, steeped in pure water for 0.5 h, heated to boiling, decocted for 2 h, filtered from the aqueous extract, then the residue will be added to pure water and decocted for 1 h. The two liquid extracts will be combined, settled, filtered and concentrated into a thick paste (relative density 1.32–1.35, 50 °C), with a certain amount of soluble starch and dextrin as auxiliary materials to assist in forming, and processed into 1000 g concentrated granules by spray drying. The final Wangbi granule is equivalent to 27.88 g of the original drugs per 12 g (ter in die, a total of about 83.63 g per day) and sealed with aluminum-plastic composite film (BOPP/AL/CPE) packaging material. The Wangbi granule needs to be dissolved in hot water for each use. The placebo consists of one tenth of the dosage of Wangbi granule, starch, caramel color and bitter agent. Its appearance and odor are the same as those of Wangbi granule. The study drugs are from the same batch, purchased from Good Nurse Pharmaceutical (Liaoning, China), coded and kept under lock and key by the drug administrator in a special cabinet at room temperature and dry place. On the day of enrollment, patients will be given these medications.

Table 2 Components of Wangbi granule (intervention drug)

Except for the experimental drugs, the participants are not allowed to use other botanical, zoological and Western medicines with immunosuppressive or immunomodulatory effects. All treatments that may improve RA, such as acupuncture and massage, will be banned during the trial. If a patient has special circumstances during the observation period, for instance. In that case, when pain is unbearable, drugs such as low-dose NSAIDs can be used in combination under the direction of the investigator, and all drug use outside the study protocol must be recorded in detail.

The participants will take the drugs daily for 12 consecutive weeks under self-monitoring. During the course of the medication intervention, we will strictly ensure that participants are adequately adherent. After the participant has formally decided to participate in the clinical study, the investigator will explain the entire trial process, including the time points at which various types of information will be collected, the meaning of every terminology in the questionnaire, the frequency and method of how participants need to take drugs. Participants are required to fill out daily health monitoring forms to record medication intake and changes in the condition so that the investigator can check. Participants will be asked to bring all leftover drugs to every follow-up visit to check their compliance. Investigator faithfully recorded the number of drugs received, taken and returned by the participant and promptly recorded them on the case report form. Once a participant enrolled in the study, the drugs used and the tests involved will be covered by the study center and the participant will be reimbursed a certain amount of grants when the trial is completed in full. Through these incentives, participants will maximize their enthusiasm for the trial, which is expected to improve in RA clinical conditions.


The efficacy of Wangbi granule will be observed and the main outcome is DAS28 [19], assessed by a dedicated rheumatologist (associate senior physician or better). The changes in the DAS28 score will be recorded during the observation period. Moreover, participants are considered to have achieved deep clinical remission when the calculated DAS28 score is lower than 2.6.

Secondary outcomes include patient-reported outcomes (symptom score) [18], ACR50 [20], fatigue scale-14 (FS-14) [21], visual analogue scale for pain (VAS) [22], health assessment questionnaire disability index (HAQ-DI) [23] and biological markers [24] such as CRP and ESR. Specific secondary outcomes are shown in Table 3.

Table 3 Secondary outcomes of the trial


Medications including methotrexate, tofacitinib, and Wangbi granule are all commonly used for RA and are not expected to cause unacceptable side effects compared to their therapeutic effects. If an adverse reaction is suspected, treatment will be stopped immediately with the permission of the Principal Investigator. During the trial period, investigator will provide participants with free trial drugs. Participants will have access to some free tests and receive a set amount of subsidy.

An adverse event is defined as any adverse medical event that occurs between the time the participant signs the informed consent and the last follow-up visit, whether or not it is causally related to the study drug. Adverse events will be monitored continuously during the treatment period, regardless of whether adverse events are related to the trial drug, the investigators should fill out the record form truthfully and in detail. A serious adverse event, such as a new or previous exacerbation of the patient’s disease during treatment, must be reported within 24 h. Termination of the trial should be considered when additional immunosuppressive drugs or other medications, surgery or other physical therapy associated with the improvement of RA are indeed required. Such a sample will be treated as an off-case. The study team will continue to track the progress of adverse events.

Allocation and blinding

A central randomization system will be applied in this study, with an independent contract research organization (CRO) implementing the randomized assignment and drug dispensing in each subcenter. Participants will be randomized to either the intervention or control group, and stratified block group randomization will be used for participant randomization. In the random assignment process, participants are first allowed to enter the zone group and then are randomly allocated. The length of the zone group is set to 4, and the six permutations obtained are designated as AABB, ABAB, ABBA, BAAB, BABA, BBAA, with A and B representing the intervention or control group, whose exact meaning is known only to the designer. Subsequently, a string of random numbers is generated by SPSS software, and the allocation sequence is obtained by selecting numbers between 1 and 6 and arranging the district groups in the order of random numbers. Once each subcenter has determined the eligibility of participants and obtained the written consent to participate in the trial, a number will be requested from the randomization manager. The complete sequence of generated assignments is kept at the CRO, and the designer will place them in sequentially numbered sealed opaque envelopes and store them in a locked cabinet.

Researchers, participants and statistical analysts will be blinded to group assignment. After all cases are included, all clinical data will be entered into the database and verified, and the data will be locked after confirmation of accuracy. Groups A and B will be divided into two groups at the first unblinding, but it is not clear which group is the intervention group. After the statistical analysis, the results will be processed and the second unblinding will be carried out to find out whether group A and group B represent the intervention group or the control group. If a serious adverse event or unexpected adverse reaction occurs during the trial, the patient’s blinding status will be broken with the consent of the Principal Investigator (PI), and all such cases will be reported to the Clinical Research Ethics Committee of the China-Japan Friendship Hospital.

Participant timeline

Participants in the trial are required to be recorded four times, with visits at enrollment (in the hospital), 4 weeks (in the hospital), 8 weeks (by telephone follow-up), and 12 weeks (in the hospital) after intervention, each taking approximately 15–20 min. In addition, participants are asked to have an additional telephone follow-up visit 1 month after completion of the study, regardless of the type of intervention (Table 4).

Table 4 Time schedule of enrolment, intervention and outcome measures of the trial

Sample size calculation

The study used superiority design approach. Due to the lack of clinical studies of methotrexate and tofacitinib in combination with Wangbi granule, we refer to the previous studies of methotrexate in combination with Wangbi granule for the treatment of RA [25]. In order to observe the deep remission effect of the Wangbi granule on RA condition, the final DAS28 score of the intervention group needs to be at least 0.5 points lower than that of the control group, so the cut-off value δ takes − 0.5. We adopted single-sided calculation whereα is 0.025, β is 0.2, and the sample size is 1:1, then the single group sample size of 155 cases is obtained. Considering a shedding rate of 10%, 170 cases are needed in each group, and the final total sample size is 340.According to the plan, as the lead center, China-Japan Friendship Hospital will complete the intake of 90 samples, and the remaining 5 centers will equally distribute the remaining 250 samples.

Statistical analysis

All analysis and data visualization will be performed using IBM SPSS (Version 25.0), R (Version 4.1.1).

Baseline data will be displayed using descriptive statistics (eg, means, SD, median, IQR, proportions). We will test the group balance achieved by randomization through appropriate statistical tests (eg, Student’s t tests, Pearson’s χ2 tests). Outcomes with a continuous distribution will be compared between groups using the mean (Student’s t test) and Pearson’s χ2 test will be used for binary categorical data where categorical variables are expressed as frequencies and percentages and continuous variables are expressed as means and SD.

Preliminary statistical analysis of the primary outcome data will be performed according to the intention-to-treat principle, and the changes in DAS28 will be compared between patients treated with Wangbi granule and Wangbi placebo, and report the rate of deep remission. Further, two-way repeated measures analysis of variance (ANOVA) will be used to examine any interaction effects of the outcome variables between the two groups at the four time points. Mauchly’s sphericity test will be used to examine the spherical assumptions of the repeated measures ANOVA. Bonferroni-corrected post hoc multiple comparisons will be used to examine simple effects between groups at different time points and at different time points for each group.

Sensitivity analysis will be an essential part of the statistical analysis process to complement the interpretation of the results. Depending on the specifics of the data, the full samples will be divided into subgroups based on information about additional drugs (e.g. NSAIDs), co-existing underlying conditions (e.g. hypertension, diabetes), long-term use of other drugs, etc. The calculations will be re-run in each subgroup to verify the validity of the results. When necessary, a per protocol set (PPS) analysis will be part of the sensitivity analysis. If any variable has no more than 20% missing values, the MICE package in R will be used for multiple interpolation to replace it. For the statistical process, P < 0.05 is considered statistically significant.

Data management

Investigators and participants obtain the required information in person or by telephone, and investigators will consult the hospital’s medical records system to complete additional details. All the data obtained are recorded in the special paper case report form. The information obtained from the last recording will be used as the final data for participants who withdrew. After the CRO collects the paper documents returned by each research center, these data are stored in a special database for unified management. Epidata software will be used to establish the corresponding database, and the data will be entered synchronously by different data managers, using the two-entry method. The CRO will be in charge of data management. The biological sample are stored in the bio-sample bank of China-Japan Friendship Hospital.

Quality control

Due to the need to collect data on some of the more subjective scales, such as symptom score, FS-14, etc. The PI will provide adequate training to the investigators at each sub-center before the start of the trial to ensure that the investigators understand the complete study protocol and operational methods. The principal investigators of each research center must be an associate senior physician or better. Two investigators will complete the participant’s rating at each follow-up visit at the same time, and the average will be taken as the final record to reduce the bias of subjective assessment. A third investigator will assist in the assessment when the difference in results is too wide. After participants enrolled in the trial, the investigators will educate them to ensure that participants know exactly how to judge their condition and score subjectively.

Supervisors are appointed by the PI to ensure that the rights and interests of subjects in clinical trials are protected, that data in trial records and reports are accurate and complete, to oversee the implementation of clinical trial protocols, drug clinical trial management norms and relevant regulations, and to conduct regular on-site supervision visits to each center. For objective indicators, paper reports need to be retained for subsequent verification.

The trial is monitored by the Clinical Research Ethics Committee of the China-Japan Friendship Hospital. Moreover, the third-party independent CRO will perform quality control throughout the trial process.


We expect that the current study can address a major concern in the field of RA treatment. Most patients still suffer from persistent symptoms and elevated inflammatory factors after a stronger medication regimen, in which case simply increasing the drug dose or continuing the combination with other DMARDs does not continue to improve the condition, but rather raises the risk of side effects [26]. When Wangbi granule is newly added to the management of RA as a primary therapeutic intervention, there may be additional benefits for patients. This will further guide us to develop improved treatment and home management guidelines to better respond to changes in patient health status.

In addition to assessing clinical efficacy and providing evidence-based medical evidence, this study also attempts to provide assistance in the precise treatment of RA through the detection of biological samples (e.g., inflammatory factors in blood). In the course of systemic anti-inflammatory treatment, synovitis-targeted therapies provide support for improvement, and most of the biologically targeted agents that exist today target key cytokines [27], mainly TNF, IL-6 family, etc. Chinese medicine may play a more important role at the pathophysiological level because of its unique multi-targeted effects, and studies have proved that Wangbi granule can modulate immune and cytokines and intervene at the proteomic level [28]. This trial can further explore the possible molecular regulatory network on this basis, provide therapeutic targets from a multi-omics perspective, and provide practical basis for precise treatment of integrated traditional Chinese and Western medicine.

Inevitably, however, there are some limitations in this study. In the judgment of the disease, most of the scores are based on the subjective feelings of the patients, which may have some bias. In addition, longer-term follow-up will not be designed (participants in this study will complete 3 months of treatment and 1 month of follow-up after treatment) due to cost constraints.


This study is a multicenter, triple-blind, randomized, placebo-controlled trial that potentially provides an effective treatment strategy for the integration of traditional Chinese and Western medicine in the treatment of RA.

Availability of data and materials

The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors.



American College of Rheumatology 50% response criteria


Biologic disease-modifying antirheumatic drugs


Contract research organization


C-reactive protein


Conventional synthetic disease-modifying antirheumatic drugs


Disease activity score derivative for 28 joints


Erythrocyte sedimentation rate


Fatigue scale-14


Health assessment questionnaire disability index


Non-steroidal antiinflammatory drugs


Principal Investigator


Per protocol set


Rheumatoid arthritis


Visual analogue scale for pain


  1. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174–87.

    Article  PubMed  Google Scholar 

  3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

    Article  CAS  PubMed  Google Scholar 

  4. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–48.

    Article  PubMed  Google Scholar 

  5. Conigliaro P, Triggianese P, De Martino E, Fonti GL, Chimenti MS, Sunzini F, et al. Challenges in the treatment of rheumatoid arthritis. Autoimmun Rev. 2019;18(7):706–13.

    Article  PubMed  Google Scholar 

  6. Pope JE. Management of fatigue in rheumatoid arthritis. RMD Open. 2020;6(1): e001084.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mathias K, Amarnani A, Pal N, Karri J, Arkfeld D, Hagedorn JM, et al. Chronic pain in patients with rheumatoid arthritis. Curr Pain Headache Rep. 2021;25(9):59.

    Article  PubMed  Google Scholar 

  8. Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–68.

    Article  CAS  PubMed  Google Scholar 

  9. Wang Y, Chen S, Du K, Liang C, Wang S, Owusu Boadi E, et al. Traditional herbal medicine: therapeutic potential in rheumatoid arthritis. J Ethnopharmacol. 2021;279: 114368.

    Article  CAS  PubMed  Google Scholar 

  10. Zhao J, Zha Q, Jiang M, Cao H, Lu A. Expert consensus on the treatment of rheumatoid arthritis with Chinese patent medicines. J Altern Complement Med. 2013;19(2):111–8.

    Article  CAS  PubMed  Google Scholar 

  11. Shu H, Shi Y, Li L, Zhao N, Lu C, Lu A, et al. Dissecting the molecular mechanism of Wang-Bi capsule in the treatment of experimental rheumatoid arthritis based on synovial tissue proteomic analysis. J Immunol Res. 2021;10(18):5539008.

    Google Scholar 

  12. Li H, You Y, Jiang B, Li H, Li X, Wu W, et al. Wang-Bi tablet ameliorates DMM-induced knee osteoarthritis through suppressing the activation of p38-MAPK and NF-κB signaling pathways in mice. Evid Based Complement Altern Med. 2021;8(13):3930826.

    Google Scholar 

  13. Chen WH, Weng XS, Yan XP, Liu W, Jin YH, Lin N, et al. Expert consensus on clinical application of Wangbi tablets in treating rheumatoid arthritis and knee osteoarthritis. China J Chin Mater Med. 2021;46(17):4569–74.

    Google Scholar 

  14. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340: c332.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.

    Article  PubMed  Google Scholar 

  17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.

    Article  CAS  PubMed  Google Scholar 

  18. Jiang Q, Wang HL, Gong X, Luo CG. Guidelines of diagnosis and treatment of rheumatoid arthritis disease and syndrome combination. J Tradit Chin Med. 2018;59:1794–800.

    Google Scholar 

  19. Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: patient (PtGA) and provider (PrGA) global assessment of disease activity, disease activity score (DAS) and disease activity score with 28-joint counts (DAS28), simplified disease activity index (SDAI), clinical disease activity index (CDAI), patient activity score (PAS) and patient activity score-II (PASII), routine assessment of patient index data (RAPID), rheumatoid arthritis disease activity index (RADAI) and rheumatoid arthritis disease activity index-5 (RADAI-5), chronic arthritis systemic index (CASI), patient-based disease activity score with ESR (PDAS1) and patient-based disease activity score without ESR (PDAS2), and mean overall index for rheumatoid arthritis (MOI-RA). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S14-36.

    Article  PubMed  Google Scholar 

  20. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193–202.

  21. Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol rheumatoid arthritis fatigue multi-dimensional questionnaire (BRAF MDQ), Bristol rheumatoid arthritis fatigue numerical rating scales (BRAF NRS) for severity, effect, and coping, Chalder fatigue questionnaire (CFQ), checklist individual strength (CIS20R and CIS8R), fatigue severity scale (FSS), functional assessment chronic illness therapy (fatigue) (FACIT-F), multi-dimensional assessment of fatigue (MAF), multi-dimensional fatigue inventory (MFI), pediatric quality of life (PedsQL) multi-dimensional fatigue scale, profile of fatigue (ProF), Short form 36 vitality subscale (SF-36 VT), and visual analog scales (VAS). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S263-286.

    Article  PubMed  Google Scholar 

  22. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14(7):798–804.

    Article  PubMed  Google Scholar 

  23. Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: health assessment questionnaire disability index (HAQ), modified health assessment questionnaire (MHAQ), multidimensional health assessment questionnaire (MDHAQ), health assessment questionnaire II (HAQ-II), improved health assessment questionnaire (improved HAQ), and rheumatoid arthritis quality of life (RAQoL). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S4-13.

    Article  PubMed  Google Scholar 

  24. Lange E, Kucharski D, Svedlund S, Svensson K, Bertholds G, Gjertsson I, et al. Effects of aerobic and resistance exercise in older adults with rheumatoid arthritis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2019;71(1):61–70.

    Article  PubMed  Google Scholar 

  25. Shuai B, Shen L, Ma C, Yang YP, Lu FR, Liao Y, et al. Effect of Wangbi pill combined with methotrexate on serum DKK-1 expression and synovial erosion in patients with rheumatoid arthritis. Chin J Tradit Med Traumatol Orthop. 2020;28(06):16–20.

    Google Scholar 

  26. Verhoef LM, Tweehuysen L, Hulscher ME, Fautrel B, den Broeder AA. bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search. Rheumatol Ther. 2017;4(1):1–24.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Pandolfi F, Franza L. Interleukin-6 in rheumatoid arthritis. Int J Mol Sci. 2020;21(15):5238.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Shu H, Zhao H, Shi Y, Lu C, Li L, Zhao N, et al. Transcriptomics-based analysis of the mechanism by which Wang-Bi capsule alleviates joint destruction in rats with collagen-induced arthritis. Chin Med. 2021;16(1):31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We appreciate the efforts and cooperation of all research staff and patients involving this study. All authors would like to thank Liaoning Good Nurse Pharmaceutical (Group) Co., Ltd. (Benxi City, Liaoning Province, China) for providing the research drugs used in this study. The design, management, analysis, and reporting of the study are entirely independent of the manufacturers.

Trial status

The trial is expected to start in February 2023, with an expected inclusion period of 2–3 years and expected to end in June 2025.


The work was supported by the National High Level Hospital Clinical Research Funding (No. 2022-NHLHCRF-LX-02-02).

Author information

Authors and Affiliations



XY, LMT and TQW conceptualized the trial with support from co-authors. WJP, WZH, LTY, ZLB, ZQH, WXC, LZB, WY, ZJY, LYQ, LRL, ZN, LMT, TQW and XY participated in creating the study design. WJP and WZH made the first draft of the manuscript. XY participated in creating the statistical analysis plan. All authors reviewed and revised the manuscript critically for important intellectual content. All authors reviewed the final manuscript as submitted. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yuan Xu, Mengtao Li or Qingwen Tao.

Ethics declarations

Ethics approval and consent to participate

Ethics approval was obtained from the Clinical Research Ethics Committee of the China-Japan Friendship Hospital (No. 2022-KY-155) on 25 August 2022. The study has been registered in the ClinicalTrials Registry ( on 15 September 2022. Wangbi granule used in the trial is a marketed drug approved by China National Medical Products Administration, and its manufacturer, Good Nurse Pharmaceutical, Liaoning, China, has been notified of the trial and has provided the test medication and placebo for this trial. All participants will sign a written informed consent prior to inclusion and will be managed exclusively by a trained clinician during the study. The study will follow the Declaration of Helsink, participants can make the decision to withdraw from the trial at any time, and all data that may reveal personal privacy will be hidden.

Consent for publication

Not applicable.

Competing interests

All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Wang, Z., Lan, T. et al. Wangbi granule as a combination therapy to achieve clinical deep remission in rheumatoid arthritis: protocol for a multicenter, triple-blind, randomised, placebo-controlled trial. Chin Med 18, 22 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: